Mechanisms of atrial natriuretic factor-induced vasodilation.
ANF can potentially elicit vasorelaxation in vitro which is typically associated with an elevation in tissue levels of cGMP. Hypotension with vasodilation can be observed upon injection of ANF in vivo, however, infusion of the peptide often results in a decreased blood pressure due to a fall in cardiac output, This apparent discrepancy may reflect some of the distinguishing characteristics of ANF-induced vasorelaxation which include activation of particulate guanylate cyclase, a marked regional vascular selectivity, species differences in the relaxation profile and a variable sensitivity depending on the type and degree of contractile preload.
Winquist
R J
RJ
Department of Pharmacology, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 06877.
Hintze
T H
TH
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000494:pharmacology*; D001775:Blood Circulation / Q000187:drug effects; D006152:Cyclic GMP / Q000378:metabolism; D009131:Muscle, Smooth, Vascular / Q000187:drug effects* / Q000378:metabolism; D017461:Receptors, Atrial Natriuretic Factor; D011956:Receptors, Cell Surface / Q000378:metabolism; D013045:Species Specificity; D014664:Vasodilation / Q000187:drug effects*
D011956:Receptors, Cell Surface; D009320:Atrial Natriuretic Factor; D017461:Receptors, Atrial Natriuretic Factor; D006152:Cyclic GMP